Tags

Type your tag names separated by a space and hit enter

Lamifiban.
Drugs. 1999 Feb; 57(2):215-21; discussion 222-3.D

Abstract

Lamifiban is an intravenously administered, selective, reversible, nonpeptide glycoprotein IIb/IIIa receptor antagonist which inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets. In trials in patients with non-Q wave myocardial infarction (MI) or unstable angina pectoris (PARAGON A and the Canadian Lamifiban Study), the incidence of clinical events at 30 days in patients receiving lamifiban (1 to 5 microg/min) was not significantly different from that in patients receiving aspirin plus heparin or aspirin alone. In PARAGON A, the incidence of clinical events at 6 months was significantly lower after lamifiban (with or without heparin) and aspirin therapy than after standard heparin and aspirin therapy. A large phase III trial (PARAGON B) is under way comparing lamifiban plus aspirin and heparin with standard aspirin and heparin therapy in patients with non-Q wave MI or unstable angina pectoris. In clinical trials, the most common adverse events associated with lamifiban were bleeding complications which were increased by the concomitant administration of heparin.

Authors+Show Affiliations

Adis International Limited, Auckland, Mairangi Bay, New Zealand. demail@adis.co.nzNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10188762

Citation

Dooley, M, and K L. Goa. "Lamifiban." Drugs, vol. 57, no. 2, 1999, pp. 215-21; discussion 222-3.
Dooley M, Goa KL. Lamifiban. Drugs. 1999;57(2):215-21; discussion 222-3.
Dooley, M., & Goa, K. L. (1999). Lamifiban. Drugs, 57(2), 215-21; discussion 222-3.
Dooley M, Goa KL. Lamifiban. Drugs. 1999;57(2):215-21; discussion 222-3. PubMed PMID: 10188762.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lamifiban. AU - Dooley,M, AU - Goa,K L, PY - 1999/4/3/pubmed PY - 1999/4/3/medline PY - 1999/4/3/entrez SP - 215-21; discussion 222-3 JF - Drugs JO - Drugs VL - 57 IS - 2 N2 - Lamifiban is an intravenously administered, selective, reversible, nonpeptide glycoprotein IIb/IIIa receptor antagonist which inhibits platelet aggregation and thrombus formation by preventing the binding of fibrinogen to platelets. In trials in patients with non-Q wave myocardial infarction (MI) or unstable angina pectoris (PARAGON A and the Canadian Lamifiban Study), the incidence of clinical events at 30 days in patients receiving lamifiban (1 to 5 microg/min) was not significantly different from that in patients receiving aspirin plus heparin or aspirin alone. In PARAGON A, the incidence of clinical events at 6 months was significantly lower after lamifiban (with or without heparin) and aspirin therapy than after standard heparin and aspirin therapy. A large phase III trial (PARAGON B) is under way comparing lamifiban plus aspirin and heparin with standard aspirin and heparin therapy in patients with non-Q wave MI or unstable angina pectoris. In clinical trials, the most common adverse events associated with lamifiban were bleeding complications which were increased by the concomitant administration of heparin. SN - 0012-6667 UR - https://www.unboundmedicine.com/medline/citation/10188762/Lamifiban_ DB - PRIME DP - Unbound Medicine ER -